Program
follitropin delta
Also written as “Follitropin delta”, “FE 999049” and “Follitropin Delta (FE 999049)”.
Its studies are mostly in Infertility · Infertility, Female, led by 3 companies.
Drug pageFollitropin delta: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ferring Pharmaceuticalsits history only | 150 open or running | phase 3since Aug 16, 2013 | Aug 30, 2011 | none ahead |
| Clinique Ovoits history only | 21 open or running | phase 2since Jan 30, 2019 | Jan 30, 2019 | none ahead |
| Dr François Bissonnette | 10 open or running | no phasesince Mar 8, 2018 | Mar 8, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Dr François Bissonnette only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 8, 2018First study: no phase study in Fertility DisordersFirst studyNCT03483545 · 160 enrolled · Canada
TargetBeta
“Follicle stimulating hormone receptor agonist”ChEMBL 37, by rule
Other programs on FSHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| follitropin alfarule | Merck KGaA, Darmstadt, Germany | phase 4 | 26 |
| Follicle Stimulating Hormonerule | glycotope-gmbh | phase 4 | 6 |
Studies
The one study Dr François Bissonnette leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT03483545Fertility Disorders · Canada | – | Completed | Jul 31, 2019 | 160 |
How it is read
Names in the registry
- “Follitropin delta”, 5 entries
- “FE 999049”, 4 entries
- “Follitropin Delta (FE 999049)”, 3 entries
- “Combination therapy : Follitropin delta and HP-hMG”, 1 entry
- “REKOVELLE (Follitropin Delta)”, 1 entry
Conditions, from the studies’ own filings
- Infertility, 11 studies
- Infertility, Female, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.